Glypressin (Terlipressin Acetate)

Glypressin is indicated for several acute conditions where rapid vasoconstriction is required. These uses reflect its ability to raise systemic vascular resistance and enhance organ perfusion.

• Management of acute esophageal variceal bleeding in patients with portal hypertension.
• Treatment of hepatorenal syndrome type 1 to improve renal function.
• Off‑label use for selected cases of septic shock when conventional therapy is insufficient.
• Support of hemodynamics during liver transplantation procedures.
• Adjunct therapy in severe hypotension associated with advanced liver disease.

The safety profile of Glypressin includes both frequent, typically mild reactions and less common, potentially serious events.

Common

• Transient headache or dizziness, usually resolving after infusion cessation.
• Nausea, vomiting, or abdominal discomfort that may be mild and self‑limited.
• Flushing, warmth, or mild skin erythema at the infusion site.
• Mild increase in serum sodium levels observed during therapy.

Serious

• Severe hypertension or hypertensive crisis that may require antihypertensive treatment.
• Cardiac arrhythmias, including tachycardia or atrial fibrillation, potentially needing monitoring.
• Ischemic complications such as myocardial infarction, limb ischemia, or mesenteric ischemia.
• Acute renal failure or worsening renal function, especially in patients with pre‑existing kidney disease.

When prescribing Glypressin, clinicians should evaluate several precautionary factors to minimize risk and ensure appropriate use.

• Assess baseline blood pressure; avoid use in patients with uncontrolled hypertension.
• Evaluate cardiac history, as Glypressin may exacerbate ischemic heart disease.
• Monitor renal function before and during therapy, especially in those with existing kidney impairment.
• Use cautiously in patients with peripheral vascular disease due to risk of limb ischemia.
• Consider potential fetal risk; Glypressin is contraindicated in pregnancy unless benefits outweigh unknown risks.
• Review concomitant vasoconstrictive agents to prevent additive hypertensive effects.

Glypressin can interact with other medications that influence vascular tone, cardiac rhythm, or renal function.

Avoid

• Concurrent use with other potent vasoconstrictors (e.g., norepinephrine, phenylephrine) that may cause severe hypertension.
• Combination with monoamine oxidase inhibitors or serotonergic agents, which could increase risk of vasospasm.
• Simultaneous administration with QT‑prolonging drugs, as combined effects may precipitate arrhythmias.

Use with caution

• Co‑administration with beta‑blockers, which may mask tachycardia signs.
• Concurrent diuretics, requiring close monitoring of electrolytes and fluid balance.
• Combination with anticoagulants, as ischemic complications may be amplified.
• Concomitant corticosteroids, which can enhance fluid retention and raise blood pressure.
• Use with drugs affecting hepatic metabolism (e.g., CYP450 inhibitors) because altered clearance may modify drug response.